{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-027209","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2026-06-04T13:00:32+00:00","discovered_at":"2026-06-04T13:01:00.241045+00:00","generated_at":"2026-06-04T13:01:24.379291+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Lipocine to host virtual KOL event on LPCN 1154 for postpartum depression on June 12, 2026","bullets":["Virtual KOL event focused on unmet needs in postpartum depression and clinical profile of LPCN 1154 (oral brexanolone).","Event scheduled for June 12, 2026 at 11:00 AM ET; advance registration required.","LPCN 1154 Phase 3 trial showed efficacy in subgroup analysis excluding outlier site; 100% dosing completion.","PPD affects ~1 in 5 U.S. women; annual economic burden estimated at $14.2 billion."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-027209","json":"https://secwatch.observer/filing/0001493152-26-027209.json","markdown":"https://secwatch.observer/filing/0001493152-26-027209.md","text":"https://secwatch.observer/filing/0001493152-26-027209.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226027209/0001493152-26-027209-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226027209/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:01:24.379291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}